Testosterone Enanthate + Finasteride

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Male Hypogonadism

Conditions

Male Hypogonadism, Muscle Atrophy, Sarcopenia, Benign Prostate Hypertrophy

Trial Timeline

Jan 1, 2007 → Oct 1, 2014

NCT ID

NCT00475501

About Testosterone Enanthate + Finasteride

Testosterone Enanthate + Finasteride is a phase 2 stage product being developed by Merck for Male Hypogonadism. The current trial status is completed. This product is registered under clinical trial identifier NCT00475501. Target conditions include Male Hypogonadism, Muscle Atrophy, Sarcopenia.

What happened to similar drugs?

3 of 20 similar drugs in Male Hypogonadism were approved

Approved (3) Terminated (0) Active (17)

✅Eribulin Injection [Halaven] + Paclitaxel injectionEisaiApproved

✅CFA + rFSHMerckApproved

✅Treatment A + Blood samples for the analysis of sildenafil in plasma + Treatment B + Treatment CPfizerApproved

🔄Gemcitabine + liposomal doxorubicinEli LillyPhase 3

🔄Gemcitabine + Paclitaxel + CarboplatinEli LillyPhase 3

🔄Abemaciclib 50 MG; 150mg 1-0-1 per osEli LillyPhase 3

🔄SHR6390 + placeboJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00475501	Phase 2	Completed	Jan 1, 2007	Oct 1, 2014	Male Hypogonadism

Competing Products

20 competing products in Male Hypogonadism

See all competitors

Product	Company	Stage	Hype Score
Fulvestrant	Dr. Reddy's Laboratories	Pre-clinical	19
ENZ215 + EU Sourced Prolia + US Sourced Prolia	Alkem Laboratories	Phase 1	29
Fulvestrant + Abemaciclib	Eli Lilly	Phase 2	39
Gemcitabine + liposomal doxorubicin	Eli Lilly	Phase 3	40
[14C]-LY3549492 + LY3549492 + [14C]-LY3549492	Eli Lilly	Phase 1	29
CT-P41 + EU-approved Prolia	Celltrion	Phase 1	29
CT-P55 + US-licensed Cosentyx + EU-approved Cosentyx	Celltrion	Phase 1	29
CT-P52	Celltrion	Phase 1	36
CT-P43 + CT-P43	Celltrion	Phase 1	29
Telmisartan + Amlodipine + Rosuvastatin	Yuhan	Phase 1	29
ASP3325 + Placebo	Astellas Pharma	Phase 1	29
TRK-100STP	Astellas Pharma	Phase 1	29
Ensitrelvir	Shionogi	Phase 1	29
E6011 + E6011 Matching Placebo	Eisai	Phase 1	29
E6130 + Placebo	Eisai	Phase 1	29
Eribulin Injection [Halaven] + Paclitaxel injection	Eisai	Approved	39
E3112	Eisai	Phase 1	29
E2022 Tape Formulation	Eisai	Phase 1	29
Placebo + E3112	Eisai	Phase 1	29
[14C]-E6007	Eisai	Phase 1	29